The ARK Genomic Revolution ETF rose about 7.9% on Wednesday, led by outsized gains in Absci (+38.3%) and Adaptive Biotechnologies (+13.7%). The move signals strong risk-on momentum in genomics and biotech names, with ETF-level performance likely driven by sharp stock-specific upside in key holdings.
The ARK Genomic Revolution ETF rose about 7.9% on Wednesday, led by outsized gains in Absci (+38.3%) and Adaptive Biotechnologies (+13.7%). The move signals strong risk-on momentum in genomics and biotech names, with ETF-level performance likely driven by sharp stock-specific upside in key holdings.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.62
Ticker Sentiment
